GlassScriptPhysician profile
Robert M Mahaffey
NPI 1013971191
$8,243.55
in general payments reported to CMS, 2019-2025
48 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $1,071 · 2021: $2,042 · 2022: $1,663 · 2023: $781 · 2024: $531 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $880.55 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $848.92 | 2019-2024 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $532.47 | 2019-2024 | Yupelri |
| Daiichi Sankyo INC. | $502.44 | 2019-2022 | |
| Amgen INC. | $495.10 | 2019-2024 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $450.84 | 2019-2023 | Arexvy, Shingrix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.81 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $394.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $336.87 | 2019-2024 | Verquvo, Capvaxive, Gardasil |
| Pfizer INC. | $314.53 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $245.14 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.80 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $222.79 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.59 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $180.94 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.67 | 2019-2024 | |
| Insulet Corporation | $175.07 | 2024-2025 | Omnipod |
| Pulmonx Corporation | $147.06 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Si-Bone, INC. | $143.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $139.99 | 2022 | |
| Esperion Therapeutics, INC. | $138.77 | 2021 | |
| Astellas Pharma US INC | $117.13 | 2019-2025 | Veozah |
| Lilly USA, LLC | $97.93 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $85.35 | 2019-2022 | |
| Horizon Therapeutics Plc | $72.09 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.26 | 2022-2025 | Caplyta |
| Viatris Specialty LLC | $64.19 | 2025 | Yupelri |
| Exact Sciences Corporation | $57.04 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $52.21 | 2021-2022 | |
| Allergan, INC. | $48.67 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.56 | 2024 | Rexulti |
| Antares Pharma, INC. | $43.17 | 2021-2022 | |
| Axsome Therapeutics, INC. | $32.52 | 2023-2024 | Auvelity |
| Alnylam Pharmaceuticals INC. | $30.35 | 2023 | |
| Medtronic, INC. | $28.45 | 2022-2024 | Intellis Adaptivestim |
| Eisai INC. | $26.83 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $26.48 | 2019-2020 | |
| Inari Medical, INC. | $26.10 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $23.71 | 2021 | |
| Fisher & Paykel Healthcare INC | $20.12 | 2021 | |
| Currax Pharmaceuticals LLC | $19.16 | 2019 | |
| Pharmacosmos Therapeutics INC. | $17.19 | 2022 | |
| Althera Pharmaceuticals LLC | $15.61 | 2022 | |
| Alk-Abello, INC | $14.65 | 2019 | |
| Dexcom, INC. | $14.50 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $13.97 | 2022 | |
| Medtronic USA, INC. | $12.92 | 2020 | |
| Genentech USA, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mahaffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.